BioCurex, Inc. developed technology to specifically identify a cancer marker known as RECAF (TM), which is primarily found on malignant cells from a variety of cancer types, but is absent in most normal or benign cells. Currently, the company is in the process of developing and commercializing cancer diagnostic products based upon its breakthrough RECAF cancer marker technology. Their main products are Histo-RECAF, Cyro-RECAF and Serum-RECAF.
The data that was produced by the company show that cancers in the breast, lung, stomach, and prostate consist of this molecule. This identifies that RECAF is present in a variety of tissue types. In the breast cancer cases that have been studied, RECAF was found in more than 90% of them.
As a widespread cancer marker, RECAF could replace those markers in which are only available for one type of cancer, or aren’t sensitive or specific for a malignancy. The prevalence of RECAF means that it can be applied to cancers where there are no effective cancer markers.
Ricardo Moro, M.D., and CEO of BioCurex, stated, “BioCurex’s RECAF technology has the potential to revolutionize cancer detection by differentiating malignant cells from healthy ones. For this reason, we are delighted to be partnering with one of the world’s largest developer/manufacturers of advanced diagnostic products. With major facilities in the U.S., Europe, and Asia, Inverness Medical Innovations has an impressive reputation for aggressive and innovative consumer marketing. We are especially looking forward to be working with them on expanding and implementing their RECAF technology on future cancer tests.”
Let us hear your thoughts: